Zydus Cadila receives final approval from USFDA for Droxidopa capsules
Chemical

Zydus Cadila receives final approval from USFDA for Droxidopa capsules

It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.

  • By ICN Bureau | February 20, 2021

Zydus Cadila has received final approval from the USFDA to market Droxidopa Capsules, 100 mg, 200 mg, and 300 mg. Droxidopa works by constricting (narrowing) the blood vessels and increasing blood pressure.

 

It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling. It is indicated for use in people with conditions of the nervous system that can cause low blood pressure (such as Parkinson's disease, multiple system atrophy, autonomic failure, and others).

 

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 312 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Register Now to Attend Gujarat Chem & Petchem Conference 2025 on May 8-9th 2025, at Hyatt Place, Bharuch

Register Now to Attend NextGen Chemicals & Petrochemicals Summit 2025 on June 18-19th 2025, The Leela Mumbai

Other Related stories

Startups

Petrochemical

Energy

Digitization